Lyell Immunopharma, Inc. (LYEL) |
|
3.87 -0.06 (-1.53%)
|
12-06 09:31 |
|
Open: |
4.03 |
Pre. Close: |
3.93 |
|
High:
|
3.94 |
Low:
|
3.87 |
|
Volume:
|
3,987 |
Market Cap:
|
965(M) |
|
|
|
Technical analysis |
as of: 2022-12-06 9:20:14 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 6.17  One year: 7.19 |
| Support: |
Support1: 3.86 Support2: 3.21 |
| Resistance: |
Resistance1: 5.28 Resistance2: 6.15 |
| Pivot: |
4.26 |
| Moving Average: |
MA(5): 4.06 MA(20): 4.44
MA(100): 6.3 MA(250): 6.03 |
| MACD: |
MACD(12,26): -0.5  Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 5.9 %D(3): 6.9 |
| RSI: |
RSI(14): 27.7 |
| 52-week: |
High: 10.26 Low: 3.56 |
| Average Vol(K): |
3-Month: 1,153 (K) 10-Days: 962 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LYEL ] has closed above bottom band by 9.9%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.05 - 4.07 |
4.07 - 4.09 |
|
Low:
|
3.82 - 3.84 |
3.84 - 3.86 |
|
Close:
|
3.89 - 3.93 |
3.93 - 3.97 |
|
Company Description |
|
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. |
Headline News |
Thu, 01 Dec 2022
2022-12-01 | NDAQ:LYEL | Press Release | Lyell Immunopharma Inc. - Stockhouse
Tue, 29 Nov 2022
What is the Market's View on Lyell Immunopharma Inc (LYEL) Stock's Price and Volume Trends Tuesday? - InvestorsObserver
Wed, 16 Nov 2022
Where Will Lyell Immunopharma Inc (LYEL) Stock Go Next After It Is Down 0.45% in a Week? - InvestorsObserver
Wed, 09 Nov 2022
Does Lyell Immunopharma Inc (LYEL) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver
Mon, 07 Nov 2022
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors - GlobeNewswire
Tue, 25 Oct 2022
Healthcare Stocks Moving Tuesday: TSHA, RNLX, MEDP, CGC, LYEL, PXMD, IMRA, BEAT - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
249 (M) |
| Shares Float |
142 (M) |
|
% Held by Insiders
|
18 (%) |
|
% Held by Institutions
|
63.6 (%) |
|
Shares Short
|
18,990 (K) |
|
Shares Short P.Month
|
18,270 (K) |
Stock Financials |
|
EPS
|
1.47 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.28 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-559.2 |
|
Return on Assets (ttm)
|
-12.6 |
|
Return on Equity (ttm)
|
-28.7 |
|
Qtrly Rev. Growth
|
-100 |
|
Gross Profit (p.s.)
|
0.04 |
|
Sales Per Share
|
0.15 |
|
EBITDA (p.s.)
|
-0.81 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-163 (M) |
|
Levered Free Cash Flow
|
-73 (M) |
Stock Valuations |
|
PE Ratio
|
2.67 |
|
PEG Ratio
|
0.5 |
|
Price to Book value
|
1.19 |
|
Price to Sales
|
25.04 |
|
Price to Cash Flow
|
-6.03 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
